JNJ Johnson & Johnson

0  0%
Previous Close 0.00
Open 0.00
Price To book 0.00
Market Cap
Shares 0
Volume 0
Short Ratio 0.00
Av. Daily Volume 0

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial stopped early due to positive efficacy - February 8, 2017.
XARELTO (rivaroxaban)
Coronary Artery Disease or Peripheral Artery Disease
Cardiovascular Outcomes trial data due mid-2017.
Type 2 diabetes
Phase 3 trial to be completed in 2018.
Ulcerative colitis
Primary endpoint of non inferiority met - December 19, 2016.
Rilpivirine and Dolutegravir
Phase 3 data due 2019.
Diabetic Kidney Disease
Phase 3 data likely due 2019.
DARZALEX (Daratumumab)
Frontline multiple myeloma (transplant)
Phase 3 data likely due 2018.
DARZALEX (Daratumumab)
Frontline multiple myeloma (non-transplant)
Announced mid-January 2016 that Phase 2 dosing has been initiated. Internal review conducted September 2016, trial to continue as planned. Internal review due 2Q 2017.
Imetelstat - IMerge Study
Myelodysplastic syndromes
Phase 2 clinical hold lifted Nov 2014. Phase 2 initiated September 2015. Internal review conducted September 2016. Low dose discontinued, high dose enrollment suspended. Further review conducted April 2017 - further development pending FDA feedback and longer term data.
Imetelstat - IMbarkStudy
Phase 3 ongoing. Data and regulatory filings likely due 2018.
Treatment resistant depression
sNDA filing announced September 26, 2017. Priority Review. Approved January 19, 2017.
Marginal zone lymphoma
sBLA filing announced December 15, 2016. PDUFA estimate October 15, 2017.
Plaque psoriasis
sBLA filing announced December 21, 2016. PDUFA date estimate October 21, 2017.
Psoriatic arthritis (PsA)
sBLA filing announced December 21, 2016. PDUFA date estimate October 21, 2017.
Ankylosing Spondylitis
BLA submission announced November 17, 2016. PDUFA date estimate November 17, 2017.
Plaque psoriasis
BLA filing announced September 23, 2016. PDUFA estimate September 23, 2017.
Rheumatoid arthritis
PDUFA date June 17, 2017
DARZALEX (Daratumumab) + pomalidomide and dexamethasone
Relapsed or refractory multiple myeloma

Latest News

  1. Meet Carbon, Who With Big Backers Google and General Electric Wants to Revolutionize Manufacturing
  2. FDA OKs Samsung Bioepis’s Biosimilar Version Of J&J’s Remicade
  3. Samsung Bioepis wins FDA approval for rheumatoid arthritis drug that competes with Johnson & Johnson
  4. ($$) A Band-Aid for J&J
  5. U.S. FDA approves Samsung Bioepis' copy of J&J's Remicade - company
  6. South Korea's Samsung Bioepis wins U.S. FDA nod for biosimilar of J&J's Remicade
  7. Dow 30 Stock Roundup: AmEx, UNH Beat; Goldman, JNJ, Verizon Disappoint
  8. Behind JNJ’s Medical Devices Growth Trajectory
  9. Your Key Highlights from JNJ’s 1Q17 Results
  10. 3 Things Johnson & Johnson Didn't Tell You in Its Q1 Earnings Update
  11. How Johnson & Johnson’s Medical Devices Segment Fared in 1Q17
  12. Eli Lilly’s Estimate for Strattera, Other Neuroscience Products
  13. What's in Store for AbbVie (ABBV) this Earnings Season?
  14. Johnson & Johnson’s Consumer Segment’s 1Q17 Earnings
  15. 3 Reasons Gilead Sciences Is a Better Dividend Stock Than Johnson & Johnson
  16. Pharma Stock Roundup: J&J Slips on Mixed Q1, Lilly Hit by FDA CRL
  17. Top 10 Dividend Stocks to Buy Before the Next Recession
  18. Johnson & Johnson’s 1Q17 Segment-by-Segment Performance
  19. Johnson & Johnson’s 1Q17 Earnings: Changes in Its Growth Rate
  20. I Can't Believe Intuitive Surgical, Inc. Just Spent $2 Billion on Stock Buybacks